Assessment of Dissolution Profile of Aceclofenac Tablets Available in Bangladesh

  • Tajnin Ahmed Assistant Professor, Department of Pharmacy, Stamford University
  • Afia Ferdous Department of Pharmacy, Stamford University
  • Subrata Kumar Biswas Department of Pharmacy, Stamford University
  • Farhana Sharif Department of Pharmacy, Stamford University
DOI: https://doi.org/10.3329/sjps.v3i1.6790
Keywords: Bangladesh, In vitro dissolution, market preparations, aceclofenac, tablet

Abstract

The objective of this work is to find out brand-to-brand variation by applying profile comparison approaches to the dissolution data of marketed aceclofenac tablet formulations. Commercially available five brands of aceclofenac tablets were studied in simulated intestinal medium (pH 6.8) for 60 minutes time period using USP reference dissolution apparatus. Four samples complied with the USP in vitro dissolution specifications for drug release (not less than 80% of the labeled amount of Aceclofenac should be dissolved in 60 minutes). One brand (Code: S1) failed to meet the criteria; drug release was 66.85% within the specified time period.

Key words: Bangladesh; In vitro dissolution; market preparations; aceclofenac; tablet.

DOI: 10.3329/sjps.v3i1.6790

S. J. Pharm. Sci. 3(1): 1-3

Downloads

Download data is not yet available.
Abstract
1471
PDF
5961
How to Cite
Ahmed, T., Ferdous, A., Biswas, S., & Sharif, F. (1). Assessment of Dissolution Profile of Aceclofenac Tablets Available in Bangladesh. Stamford Journal of Pharmaceutical Sciences, 3(1), 1-3. https://doi.org/10.3329/sjps.v3i1.6790
Issue
Vol 3 No 1 (2010)
Section
Research Articles
As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.

Each author must agree to this statement

Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:

  • Conception or design of the study, or analysis and interpretation of data, or both
  • Drafting the article or revising it for critically important intellectual content
  • Approval of the final 'to be published' version

All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.

Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.

Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.